SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

CCCX is trending as Infleqtion, its quantum technology merger target, garners significant attention for its role in a NASA space mission and a U.S. Department of Energy contract, leading to community discussion around its perceived undervaluation against quantum peers and high expectations for its upcoming merger and NYSE debut as INFQ.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as widespread user frustration mounts over persistent platform outages and trading restrictions, especially with its ThinkorSwim platform. Despite recent positive financial updates and a substantial share buyback program, the community is actively discussing these reliability issues and the possibility of switching to alternative brokers.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending higher after an analyst upgrade to Outperform, fueled by robust long-term data for its atopic dermatitis treatment demonstrating sustained efficacy and a favorable safety profile. The community is actively discussing the drug's potential across multiple autoimmune conditions, speculating on significant valuation upside, a potential acquisition, and an anticipated resolution to its legal dispute.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as investors analyze its mixed earnings, where adjusted EPS surpassed expectations despite a revenue miss, fueling discussions around its historically low forward P/E and new management's strategic turnaround efforts amid broader fintech sector pressures.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending sharply higher following a strong earnings report that highlighted record user growth, expanding margins, and the success of its Wrapped campaign, sparking community debate over its transition from a pure growth story to a high-margin cash generator. Many users are pointing to impressive premium subscriber increases and improved profitability as reasons for the stock's significant bounce from its recent lows, viewing it as a major turning point.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending after reporting strong quarterly results that surpassed expectations, driven by solid demand from AI and cloud customers. This performance is injecting optimism into the broader software sector, with many discussing its potential to reverse recent market apprehension.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is rallying following its European CE Mark approval for the Eversense 365 CGM and the first commercial integration with the twiist automated insulin delivery system, with the community highly anticipating broader adoption of its superior one-year implantable technology despite historical management concerns and ongoing market volatility.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending amidst a sharp stock decline following its Q4 earnings report, which revealed strong revenue growth and a substantial reduction in cash burn. This has sparked significant community discussion around whether the market is overlooking the company's fundamental improvements and clearer path to profitability.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is trending sharply higher following positive top-line data from its Phase 2a trial for EVO301, an eczema drug, prompting widespread community discussion around significant upside potential and a short squeeze play, though some traders remain skeptical of its fundamentals.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to a significant stock drop after a key potential tenant terminated a $150 million funding agreement for its Project Matador data center, despite management indicating ongoing negotiations and plans to accelerate other client deals. The community is actively debating whether this presents a 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.read more...

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis Soligenix Announces Top-line Results of the Phase 2a Study of...

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Achieves Enrollment...

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J...

Shares of Soligenix rallied sharply on Tuesday, marking their best performance in nearly two months, after the biopharmaceutical company reported a key safety milestone in its confirmatory Phase 3 FLASH2 trial evaluating HyBryte (synthetic hypericin) for treating cutaneous T-cell lymphoma (CTCL).The stock jumped 20% to $1.64 on Tuesday, and added another 0.9% after hours in continued upbeat trading.The company said its first Data Monitoring Committee (DMC) meeting for the study concluded that there were no safety concerns, with HyBryte’s safety profile consistent with prior trials.&nbsp;The committee’s conclusion allows the trial to move ahead as planned, with enrollment proceeding well and an update expected in the fourth quarter of 2025, followed by a blinded interim efficacy analysis in the first half of 2026.The ongoing FLASH2 trial is a randomized, double-blind, placebo-controlled, multicenter study enrolling about 80 patients with early-stage CTCL. The study builds on Soligenix’s previous successful Phase 3 FLASH trial, which showed a 49% treatment response after 18 weeks of therapy.&nbsp;FLASH2 extends continuous double-blind treatment to 18 weeks, designed to demonstrate the drug’s effect over a more “real-world” course.HyBryte, which uses visible light-activated synthetic hypericin applied topically to skin lesions, has received orphan drug and fast-track designations from the FDA, along with&nbsp;an orphan designation from the European Medicines Agency (EMA). The company stated that its light-activated mechanism enables deeper penetration into skin tissue without causing DNA damage, positioning it as a potentially safer frontline therapy for CTCL.On Stocktwits, retail sentiment for Soligenix was ‘extremely bullish’ amid a 2,025% surge in 24-hour message volume.One bullish user described the latest Soligenix update as a strong catalyst, saying the stock appeared ready to rebound sharply after the morning dip and could test new highs in the coming sessions.&nbsp;<stembedurl>https://stocktwits.com/LithiumMakesMeHard/message/631396013</stembedurl>Another bullish user noted that the price action suggested momentum might continue, with potential for a multiday run.<stembedurl>https://stocktwits.com/bzspy/message/631352248</stembedurl><a href="https://stocktwits.com/symbol/SNGX">Soligenix’s stock</a> has declined 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Soligenix’s stock (SNGX) has declined 39% so far in 2025. (Photo credit: Getty Images)

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for the first half of 2026. 

Equity

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Current Price	$1.15
Prev Close	$1.12
Open	$1.12
Dividend Yield	0.00%
50-Day Moving Average	$1.40
Beta	0.53
Avg. Volume	191,284.15
PE Ratio	-0.31

52-Week High	$6.23
52-Week Low	$1.02
Market Capitalization	$11.3M
EPS (Annual)	-$4.98
Price to Book	1.45
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SNGX News

SNGXSoligenix Inc